GCC Hereditary Angioedema Disease Landscape

Hereditary angioedema (HAE) is an autosomal dominant disorder of C1 esterase inhibitor deficiency or dysfunction, producing recurrent, unpredictable attacks of subcutaneous and submucosal swelling. Background prevalence is roughly 1:50,000, but GCC family structures (an average of 3–4 children per family plus extended-family clustering) mean a single index diagnosis carries direct implications for 6–12 relatives. The KFSH&RC HAE registry documents an average of 3.8 affected family members identified per index case, more than double the 1.8 average reported in Europe, making family cascade screening the highest-yield diagnostic strategy available in the region.

Untreated or under-treated GCC HAE patients experience 6–12 attacks per year, with laryngeal attacks (the life-threatening presentation, carrying roughly 50% mortality if untreated) accounting for approximately 30% of episodes, a higher share than most global series. GCC emergency physicians rarely include HAE in the differential for laryngeal oedema, and general practitioners typically do not order the C4, C1-INH level, and C1-INH functional assay panel required for diagnosis unless a patient is referred to specialist allergy/immunology services at centres such as KFSH&RC, AUH, or Hamad Medical Corporation. The result: an estimated 1,200–1,500 true GCC HAE patients, of whom fewer than 200 are confirmed.

This assessment is built from GCC-specific epidemiological and clinical registry sources, triangulated against peer-reviewed regional literature and international HAE consensus guidelines. Attack frequency, laryngeal-attack share, and family cluster figures are drawn from the KFSH&RC HAE Registry and the GCC Allergy Society HAE report, cross-checked against regional peer-reviewed case series.

Formulary and access status is confirmed against NPHC and MOH listings and SFDA registration records rather than US/EU payer language, reflecting the GCC's specialist-allergy-and-immunology-centred care model and independent regulatory pathway.